YUSRI A. ELSAYED, M.D., M.H.Sc., Ph.D.
HEMATOLOGIC MALIGNANCIES DISEASE AREA STRONGHOLD LEADER
Yusri Elsayed, M.D., M.H.Sc., Ph.D. is Vice President, Hematologic Malignancies Disease Area Stronghold (DAS) Leader in the Oncology Therapeutic Area at Janssen Research & Development, LLC. In this role, Yusri leads the Hematologic Malignancies group’s scientific and business strategies for the discovery and development of breakthrough medicines that solidify Johnson and Johnson’s growing leadership position in the field.
Yusri joined Janssen in 2005 as Medical Director. Since then, he has held positions of increasing responsibility in the Oncology Therapeutic Area, including Medical Leader for YONDELIS® (trabectedin), VELCADE® (bortezomib) and several early clinical development programs. Yusri played an instrumental role in the establishment of the Hematologic Malignancies DAS and the licensing and development of Janssen’s current hematologic therapies, including IMBRUVICA® (ibrutinib), DARZALEX® (daratumumab); B cell maturation antigen chimeric antigen receptor-T cell (BCMA CAR-T) therapy and cusatuzumab. Yusri also led the Discovery teams that have successfully delivered several high-profile clinical candidates for the treatment of hematologic diseases.
Prior to joining Janssen, Yusri led early development studies of oncology drugs, including small molecules and monoclonal antibodies, at Bristol Myers Squibb. Prior to that, he was Assistant Professor of Medicine at the Cancer Institute of New Jersey at UMDNJ-Robert Wood Johnson Medical School, where he was a Principal Investigator in numerous clinical trials and authored several publications.
Yusri completed his residency in Internal Medicine at the State University of New York at Stony Brook and trained in Medical Oncology at the National Cancer Institute and in Hematology at the National Heart, Lung and Blood Institute, both of which are part of the National Institutes of Health. He is board-certified in Medical Oncology and Hematology. Yusri also earned a master’s degree in Clinical Research from Duke University and a doctorate from Kyushu University in Japan.